1M
VRTX icon

1248 Management’s Vertex Pharmaceuticals VRTX Stock Holding History

1248 Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$600K Hold
1,343
– – 0.28% 53
2025
Q4 		$609K Buy
1,343
+62
+5% +$26.7K 0.33% 52
2025
Q3 		$502K Sell
1,281
-514
-29% -$215K 0.28% 62
2025
Q2 		$799K Hold
1,795
– – 0.3% 67
2025
Q1 		$870K Sell
1,795
-270
-13% -$126K 0.37% 54
2024
Q4 		$832K Buy
+2,065
New +$957K 0.36% 61

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

1248 Management's VRTX Position: Q1 2026 in Review

1248 Management held its Vertex Pharmaceuticals (VRTX) position steady in Q1 2026 at 1,343 shares worth $600K. The position accounts for 0.28% of the portfolio, ranked #53.

1248 Management first reported a position in VRTX in Q4 2024 and has held it in 6 quarters since. The position peaked at $870K in Q1 2025. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • 1248 Management held 1,343 shares of Vertex Pharmaceuticals worth $600K as of Q1 2026.
  • 1248 Management left its Vertex Pharmaceuticals share count unchanged in Q1 2026.
  • Vertex Pharmaceuticals made up 0.28% of 1248 Management's portfolio in Q1 2026, its #53 holding.
  • 1248 Management first reported a position in Vertex Pharmaceuticals in Q4 2024 and has held it in 6 quarters since.
  • 1248 Management's Vertex Pharmaceuticals position peaked at $870K in Q1 2025.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on 1248 Management's 13F filing for Q1 2026, filed 15 May 2026.